1-3 of 3
Sandra Lejniece, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.

Michele Baccarani, Bengt Simonsson, Doris Lindörfer, Gianantonio Rosti, Antonio M Almeida, MD, PhD, Andrija Bogdanovic, Richard E. Clark, Adriana Colita, Paul A. Costeas, Laimonas Griskevicius, Joelle Guilhot, Andrzej Hellmann, MD, PhD, DSc, Karel Indrak, MD, PhD, Edward Laane, Boris Labar, MD, PhD, Tamas Masszi, MD, Sandra Lejniece, MD, Jiri Mayer, MD, Gert Ossenkoppele, Panayiotis Panayiotidis, Kimmo Porkka, MD, PhD, Susanne Saussele, Andreas Hochhaus, MD, Juan Luis Steegmann, MD, PhD, Josef Thaler, MD, Anna Turkina, Gregor Verhoef, Andrey Zaritskey, Irena Preloznik Zupan, Francesca Rancati, Lara Montrucchio, Rüdiger Hehlmann, Joerg Hasford
Journal: Blood
Blood (2009) 114 (22): 4272.
https://doi.org/10.1182/blood.V114.22.4272.4272
Published: 2009
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007